Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Precigen, Inc. (PGEN : NSDQ)

• Company Description    Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland. Number of Employees: 143

• Price / Volume Information    Yesterday's Closing Price: $3.69 Daily Weekly Monthly 20 Day Moving Average: 3,991,782 shares Shares Outstanding: 353.83 (millions) Market Capitalization: $1,305.61 (millions) Beta: 1.16 52 Week High: $5.23 52 Week Low: $0.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.40% -5.66% 12 Week -2.89% -5.67% Year To Date 229.46% 175.47%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20374 Seneca Meadows Parkway - Germantown,MD 20876 USA ph: 301-556-9900 fax: - investors@precigen.com http://www.precigen.com

• General Corporate Information    Officers Helen Sabzevari - Chief Executive Officer Randal J. Kirk - Executive Chairman Harry Thomasian Jr. - Chief Financial Officer Nancy H. Agee - Director Cesar L. Alvarez - Director Peer Information Precigen, Inc. (CORR.) Precigen, Inc. (RSPI) Precigen, Inc. (CGXP) Precigen, Inc. (BGEN) Precigen, Inc. (GTBP) Precigen, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74017N105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/18/26 Share - Related Items Shares Outstanding: 353.83 Most Recent Split Date: (:1) Beta: 1.16 Market Capitalization: $1,305.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.09 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/18/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 26.26 Price/Cash Flow: - Price / Sales: 206.94 EPS Growth vs. Year Ago Period: -22.22% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 206.61% vs. Previous Quarter: 241.36% ROE 09/30/25 - 1,066.10 06/30/25 - -842.83 03/31/25 - -279.20 ROA 09/30/25 - 57.56 06/30/25 - -78.98 03/31/25 - -79.74 Current Ratio 09/30/25 - 4.04 06/30/25 - 2.71 03/31/25 - 3.53 Quick Ratio 09/30/25 - 3.95 06/30/25 - 2.71 03/31/25 - 3.53 Operating Margin 09/30/25 - 1,248.01 06/30/25 - -2,090.07 03/31/25 - -2,043.66 Net Margin 09/30/25 - -3,912.92 06/30/25 - -2,868.66 03/31/25 - -3,728.87 Pre-Tax Margin 09/30/25 - -3,914.25 06/30/25 - -2,870.32 03/31/25 - -3,770.86 Book Value 09/30/25 - 0.14 06/30/25 - -0.12 03/31/25 - -0.05 Inventory Turnover 09/30/25 - 5.75 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 2.22 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - 68.93 06/30/25 - - 03/31/25 - 0.00

Powered by Zacks Investment Research ©